• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Evaluation of Pharmacokinetic and efficacy of Anti-PD-1/PD-L1 Antibodies and development of PBPK models.

Research Project

Project/Area Number 16H06671
Research Category

Grant-in-Aid for Research Activity Start-up

Allocation TypeSingle-year Grants
Research Field Medical pharmacy
Research InstitutionChiba University

Principal Investigator

Hatakeyama Hiroto  千葉大学, 大学院薬学研究院, 助教 (70504786)

Project Period (FY) 2016-08-26 – 2018-03-31
Project Status Completed (Fiscal Year 2017)
Budget Amount *help
¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords免疫チェックポイント阻害剤 / 抗体医薬 / 薬物動態学 / がん / PD-1 / 免疫治療
Outline of Final Research Achievements

Recently anti-PD-1 antibodies (aPD-1 Abs), anti-PD-L1 (aPD-1) Abs have been approved. However, the difference between both Abs in pharmacokinetics and anti-tumor effects have not been fully understood. In this study, we analyzed the difference between both Abs in blood concentration, biodistribution and degradation in tumor-bearing mice by using aPD-1/PD-L1 Abs labeled with radioisotopes (111In) and evaluated the relationship between PK and therapeutic effects. It was observed that aPD-L1 Abs were largely accumulated in normal tissues, especially in the spleen and liver and degraded rapidly compared with aPD-1 Abs, resulting that the blood concentration and distribution in tumors of aPD-L1 Abs tended to be low. the PK of aPD-1/PD-L1 Abs which target the same axis were not equivalent and the selectivity of expression of target molecules in both normal tissues and tumors should be considered to optimize their therapeutic efficacy. We attempted to develop PBPK models by obtained PK data.

Report

(3 results)
  • 2017 Annual Research Report   Final Research Report ( PDF )
  • 2016 Annual Research Report
  • Research Products

    (5 results)

All 2018 2017

All Journal Article (1 results) (of which Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (4 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] Investigation of Metabolomic Changes in Sunitinib-Resistant Human Renal Carcinoma 786-O Cells by Capillary Electrophoresis-Time of Flight Mass Spectrometry2018

    • Author(s)
      Hatakeyama H, Fujiwara T, Sato H, Terui A, Hisaka A.
    • Journal Title

      Biological and Pharmaceutical Bulletin

      Volume: 41 Issue: 4 Pages: 619-627

    • DOI

      10.1248/bpb.b17-00992

    • NAID

      130006602497

    • ISSN
      0918-6158, 1347-5215
    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] 担癌マウスにおける免疫チェックポイント阻害剤の組織内分布の解析とそれらが薬効特性に及ぼす影響2018

    • Author(s)
      栗野泰大、畠山浩人、鈴木博元、小久保朋美、照井亜侑、荒野泰、樋坂章博
    • Organizer
      日本薬学会第138年会
    • Related Report
      2017 Annual Research Report
  • [Presentation] 免疫チェックポイント阻害剤感受性/耐性モデルにおけるPD-L1発現量の相関性に関する検討2017

    • Author(s)
      照井亜侑、畠山浩人、樋坂章博
    • Organizer
      日本薬学会第137年会
    • Place of Presentation
      宮城、仙台国際センター
    • Year and Date
      2017-03-26
    • Related Report
      2016 Annual Research Report
  • [Presentation] Prediction of efficacy of immune checkpoint inhibitors using an immune checkpoints gene signature in non-clinical sensitive and resistant models2017

    • Author(s)
      Hatakeyama H, Terui A, Hisaka A
    • Organizer
      Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 抗PD-1抗体感受性・耐性マウスモデルの探索と感受性に影響を及ぼす因子の解析2017

    • Author(s)
      畠山浩人、照井亜侑、樋坂章博
    • Organizer
      第21回日本がん免疫学会学術総会
    • Related Report
      2017 Annual Research Report

URL: 

Published: 2016-09-02   Modified: 2019-03-29  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi